RPG Life Sciences Limited share price
NSE: RPGLIFE · ISIN INE105J01010
Key numbers
- Market cap
- ₹ 5,045 Cr
- Current price
- ₹ 3,050.60
- 52-week high / low
- ₹ 3,128 / 1,733
- Stock P/E
- 42.3
- Book value
- ₹ 366.0
- Dividend yield
- 0.79%
- ROCE
- 26.8%
- ROE
- 20.3%
- Debt to equity
- 0.03
- Sales growth (3 yrs)
- 11.3%
- Profit growth (3 yrs)
- 19.4%
- 1-year return
- 27.4%
About RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and domestic and international finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 143 | 169 | 180 | 177 | 196 |
| Operating profit | 25 | 35 | 40 | 33 | 43 |
| Net profit | 117 | 26 | 22 | 30 | 31 |
| EPS (₹) | 70.96 | 15.90 | 13.38 | 18.08 | 18.60 |
Investor presentation summary (2026-09-02)
AI summary of the presentation · tone: Positive · source document
Key numbers
- External (third-party) sales of ~95.1 Cr INR in
- Plant's revenue potential of about 200 Cr INR at full
Guidance & outlook
- FY26, apart from captive sales to RPGLS for
- Partnership expected to yield benefits in terms of
Growth & demand
- Focused on high-value low-volume niche
- Growing product pipeline with strong R&D focus
Margins & costs
- Revenue and cost synergy potential with Actis and
- criteria for high margin focus
Capex & expansion
- C Acquisition of Actis Generics by RPGAP for enhancing Product Portfolio
- full capacity with possibility of expansion at site
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.